releasing hormone


Also found in: Dictionary, Thesaurus, Financial, Encyclopedia, Wikipedia.

re·leas·ing fac·tors (RF),

1. any substance, usually of hypothalamic origin, capable of accelerating the rate of secretion of a given hormone by the anterior pituitary gland;
2. factors required in the termination phase of either RNA biosynthesis or protein biosynthesis. Synonym(s): termination factor
3. colloquial shortened form for the HMG-CoA reductase inhibitors used as antihyperlipidemic agents, whose generic names end with the suffix statin. Synonym(s): statins

releasing hormone (RH)

one of several peptides produced by the hypothalamus and secreted directly into the anterior pituitary gland via a connecting vein. Each of the releasing hormones stimulates the pituitary to secrete a specific tropic hormone. Thus corticotropic-releasing hormone stimulates the pituitary to secrete adrenocorticotropic hormone, whereas growth hormone-releasing hormone stimulates the secretion of growth hormone. Previously called releasing factor.

re·leas·ing fac·tors

(rĕ-lēs'ing fak'tŏrz)
1. Substances, usually of hypothalamic origin, capable of accelerating the rate of secretion of a given hormone by the anterior pituitary gland.
2. Factors required in the termination phase of either RNA biosynthesis or protein biosynthesis.
Synonym(s): liberins, releasing hormone.

releasing hormone

Abbreviation: RH
Any of a group of substances secreted by the hypothalamus that control or inhibit the release of various hormones. They include thyrotropin-releasing hormone, gonadotropin-releasing hormone, dopamine, growth hormone-releasing hormone, corticotropin-releasing hormone, and somatostatin. Dopamine and somatostatin act to inhibit release of the hormones they act upon.
See also: hormone
References in periodicals archive ?
0 p-values according to the [chi]2 test for categorical data (*) Student's t-test for normally distributed data or the Mann-Whitney U test for non-normally distributed quantitative data Values were means [+ or -] standard deviation and medians for non-normally distributed quantitative data GnRHa: Gonadotropin releasing hormone agonist, n: Number, y: Year, d: Day, IU: International units, hCG: Human chorionic gonadotropin, OPU: Oocyte pick-up, MII: Metaphase II, IVF: In vitro fertilization Table 2.
Gonadotropin releasing hormone analogue repairs reduced endometrial cell apoptosis in endometriosis in vitro.
Response to challenge with gonadotropin releasing hormone agonist in amother and her two sons with a constitutively activating mutation of the luteinizing hormone receptor a clinical research center study.
5 mg is the new sustained-release six-month formulation of a gonatropin- releasing hormone (GnRH) agonist analogue developed by Debiopharm Group.
Progenta's effects on shrinking fibroids were at least equivalent to that observed in women using an approved gonadotropin releasing hormone agonist ("GnRHa"), which is the most effective drug intervention for the condition.
Without a comprehensive NCD, as requested by the Company and reflected in this draft decision memorandum, Plenaxis(R) could receive inconsistent coverage among the Medicare carriers and intermediaries who may fail to distinguish this drug, the first gonadotropin releasing hormone (GnRH) antagonist approved for the treatment of advanced prostate cancer, from luteinizing hormone releasing hormone (LHRH) agonists.
The study was initiated to compare the performance of AEZS-130 against the then-available diagnostic growth hormone releasing hormone (GHRH) + Arginine (ARG) standard test.
They were randomized into one of five parallel groups; placebo, three different dose levels of Progenta(TM), and a positive control group consisting of Lucrin(R), an approved gonadotropin releasing hormone agonist ("GnRHa").
The conclusions made by the ASCO expert panel on androgen deprivation therapy (ADT) is that the use of nonsteroidal anti-androgens can be looked at as an alternative to orchiectomy or drug treatment with luteinizing hormone releasing hormone agonists (medical castration).
They have been randomized into one of five parallel groups; placebo, three different doses of Progenta(TM), and a positive control group consisting of Lupron(R), an approved gonadotropin releasing hormone agonist ("GnRHa").
They will be randomized into one of five parallel groups; placebo, three different doses of Progenta(TM), and a positive control group consisting of an approved gonadotropin releasing hormone agonist (GnRHa).